Why are shares of Piramal Pharma up over 8% in a weak market?

All 10 analysts who have coverage on Piramal Pharma, have a “buy” rating on the stock. JM Financial has the highest price target on the stock at ₹340.

Leave a Reply

Your email address will not be published. Required fields are marked *